Candel Therapeutics Inc (NASDAQ:CADL) shares, rose in value, with the stock price down by -1.87% to the previous day’s close as strong demand from buyers drove the stock to $7.36.
Actively observing the price movement in the recent trading, the stock is buoying the session at $7.50, falling within a range of $7.0 and $7.7. The value of beta (5-year monthly) is -1.283. Referring to stock’s 52-week performance, its high was $14.60, and the low was $1.45. On the whole, CADL has fluctuated by -13.05% over the past month.
With the market capitalization of Candel Therapeutics Inc currently standing at about $347.66 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-12.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CADL’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of CADL currently trading nearly -10.57% and -10.52% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 40.66, while the 7-day volatility ratio is showing 8.18% which for the 30-day chart, stands at 8.28%. Furthermore, Candel Therapeutics Inc (CADL)’s beta value is -1.14, and its average true range (ATR) is 0.75.
A comparison of Candel Therapeutics Inc (CADL) with its peers suggests the former has fared considerably weaker in the market. CADL showed an intraday change of -1.87% in today’s session so far, and over the past year, it grew by 384.21%%.
Data on historical trading for Candel Therapeutics Inc (NASDAQ:CADL) indicates that the trading volumes over the past 10 days have averaged 0.98 and over the past 3 months, they’ve averaged 1.25 million. According to company’s latest data on outstanding shares, there are 46.93 million shares outstanding.
Nearly 26.79% of Candel Therapeutics Inc’s shares belong to company insiders and institutional investors own 33.94% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.45 million shares as on 2025-03-14, resulting in a short ratio of 2.5. According to the data, the short interest in Candel Therapeutics Inc (CADL) stood at 927.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 3.45 million. The stock has fallen by -15.21% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CADL stock heading into the next quarter.
